Fig. 9.

MARF1 binds the CCR4-NOT deadenylase complex and cyclin A mRNA. a Co-immunoprecipitation using anti-HA antibody-conjugated beads followed by Western blotting. Ovary lysates expressing 3xHA-MARF1 (MAT67Tub-Gal4 → UASP-3xHA-MARF1) and those from w¹¹¹⁸ negative control were tested. b Co-immunoprecipitation using anti-HA antibody-conjugated beads followed by Western blotting. Ovary lysates expressing 3xHA-tagged MARF1 (MAT67Tub-Gal4 → UASP-3xHA-MARF1 full-length or fragments) and those from w¹¹¹⁸ negative control were tested. Black triangles indicate the detected 3xHA-tagged MARF1 proteins. c Co-immunoprecipitation using ovary lysates from w¹¹¹⁸ and anti-Not1 antibody or negative control IgG-bound protein G beads followed by Western blotting. d Fold enrichment of mRNAs relative to a control gapdh mRNA that were co-immunoprecipitated with MARF1 by anti-HA antibody-conjugated beads and were eluted from the beads normalized by w¹¹¹⁸ negative control, determined by RNA-immunoprecipitation followed by qRT-PCR. Mean ± SD (n = 3). P-value < 0.05 (Student’s t-test) is indicated by *. e ePAT assay to determine the poly-A length of cyclin A and cdk1 mRNAs in control w¹¹¹⁸ and MARF1^null stage 14 oocytes. The amplified DNA sizes determined by the capillary fragment analysis. Poly-A length of cyclin A mRNA, but not cdk1 mRNA, is longer in MARF1^null stage 14 oocytes than in control stage 14 oocytes